中国胸心血管外科临床杂志

中国胸心血管外科临床杂志

抑癌基因甲基化联合检测与肺癌早期诊断

查看全文

肺癌是世界上最常见的恶性肿瘤,也是癌症相关死亡的主要原因。由于缺乏有效的早期诊断方法,肺癌预后较差,但与晚期肺癌相比,早期肺癌生存率大大提高。因此,早期诊断肺癌至关重要。作为一种主要的表观遗传学修饰,DNA 甲基化在肺癌发生发展过程中发挥着重要作用。大量研究表明,抑癌基因甲基化检测是一种理想的肺癌早期诊断方法。随着检测技术的不断进步,可以实现多种基因的甲基化检测。研究发现多基因甲基化联合检测在穿刺病变组织、穿刺淋巴结组织等微创操作获取的组织样本以及外周血、支气管肺泡灌洗液、痰液等无创样本中均具有较高的检出率,并且较单一基因甲基化检测灵敏度及特异度更高,是一种理想的肺癌早期诊断方法。

Lung cancer is the most common malignant tumor in the world and the leading cause of cancer-related death. Due to the lack of effective early diagnosis methods, the prognosis of lung cancer is poor, but compared with advanced lung cancer, the survival rate of early lung cancer is greatly improved. Therefore, early diagnosis of lung cancer is crucial. As a major epigenetic modification, DNA methylation plays an important role in the development of lung cancer. A large number of studies have shown that detection of tumor suppressor gene methylation is an ideal early diagnosis method for lung cancer. With the continuous improvement of detection technology, methylation detection of multiple genes can be achieved. And it is found that multi-gene methylation combined detection of tissue samples obtained by minimally invasive operation such as puncture of diseased tissue and puncture of lymph node tissue, as well as the noninvasive samples such as peripheral blood, bronchoalveolar lavage fluid and sputum have higher detection rate and higher sensitivity and specificity than single gene methylation. It is an ideal method for early diagnosis of lung cancer.

关键词: 肺癌; 早期诊断; 甲基化; 联合检测

Key words: Lung cancer; Early diagnosis; Methylation; Combined detection

1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
2. 陈万青, 李贺, 孙可欣, 等. 2014年中国分地区恶性肿瘤发病和死亡分析. 中华肿瘤杂志, 2018, 27(1): 1-14.
3. Zeng H, Zheng R, Guo Y, et al. Cancer survival in China, 2003-2005: a population-based study. Int J Cancer, 2015, 136(8): 1921-1930.
4. Chansky K, Detterbeck FC, Nicholson AG, et al. The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer. J Thorac Oncol, 2017, 12(7): 1109-1121.
5. Robertson KD. DNA methylation and chromatin-unraveling the tangled web. Oncogene, 2002, 21(35): 5361-5367.
6. Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell, 2012, 150(1): 12-27.
7. Song L, Yu H, Li Y. Diagnosis of Lung Cancer by SHOX2 Gene Methylation Assay. Mol Diagn Ther, 2015, 19(3): 159-167.
8. Huang YZ, Wu W, Wu K, et al. Association of RASSF1A Promoter Methylation with Lung Cancer Risk: a Meta-analysis. Asian Pacific Journal of Cancer Prevention, 2015, 15(23): 10325-10328.
9. Tuo L, Sha S, Huayu Z, et al. P16(INK4a) gene promoter methylation as a biomarker for the diagnosis of non-small cell lung cancer: An updated meta-analysis. Thorac Cancer, 2018, 9(8): 1032-1040.
10. Pu W, Geng X, Chen S, et al. Aberrant methylation of CDH13 can be a diagnostic biomarker for lung adenocarcinoma. J Cancer, 2016, 7(15): 2280-2289.
11. Chung JH, Lee HJ, Kim BH, et al. DNA methylation profile during multistage progression of pulmonary adenocarcinomas. Virchows Arch, 2011, 459(2): 201-211.
12. Nawaz I, Qiu X, Wu H, et al. Development of a multiplex methylation specific PCR suitable for (early) detection of non-small cell lung cancer. Epigenetics, 2014, 9(8): 1138-1148.
13. Zhang Y, Wang R, Song H, et al. Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer. Cancer Lett, 2011, 303(1): 21-28.
14. Ma Y, Bai Y, Mao H, et al. A panel of promoter methylation markers for invasive and noninvasive early detection of NSCLC using a quantum dots-based FRET approach. Biosens Bioelectron, 2016, 85: 641-648.
15. Geng J, Sun J, Lin Q, et al. Methylation status of NEUROG2 and NID2 improves the diagnosis of stage I NSCLC. Oncol Lett, 2012, 3(4): 901-906.
16. Gao L, Xie E, Yu T, et al. Methylated APC and RASSF1A in multiple specimens contribute to the differential diagnosis of patients with undetermined solitary pulmonary nodules. J Thorac Dis, 2015, 7(3): 422-432.
17. Licchesi JD, Westra WH, Hooker CM, et al. Promoter hypermethylation of hallmark cancer genes in atypical adenomatous hyperplasia of the lung. Clin Cancer Res, 2008, 14(9): 2570-2578.
18. Millares L, Serra M, Andreo F, et al. Assessment of methylation status of locoregional lymph nodes in lung cancer using EBUS-NA. Clin Exp Metastasis, 2015, 32(7): 637-646.
19. van der Drift MA, Hol BE, Klaassen CH, et al. Circulating DNA is a non-invasive prognostic factor for survival in non-small cell lung cancer. Lung Cancer, 2010, 68(2): 283-287.
20. Weiss G, Schlegel A, Kottwitz D, et al. Validation of the SHOX2/PTGER4 DNA methylation marker panel for plasma-based discrimination between patients with malignant and nonmalignant lung disease. J Thorac Oncol, 2017, 12(1): 77-84.
21. Weiss G, Hasinger O, Esche S, et al. 31PD DNA methylation of SHOX2 and PTGER4 as a plasma-based tool to differentiate between patients with malignant and benign lung disease. J Thorac Oncol, 2016, 11(4): S68.
22. Hulbert A, Jusue-Torres I, Stark A, et al. Early Detection of Lung Cancer Using DNA Promoter Hypermethylation in Plasma and Sputum. Clin Can Res, 2017, 23(8): 1998.
23. Ren M, Wang C, Sheng D, et al. Methylation analysis of SHOX2 and RASSF1A in bronchoalveolar lavage fluid for early lung cancer diagnosis. Ann Diagn Pathol, 2017, 27: 57-61.
24. Zhang C, Yu W, Wang L, et al. DNA Methylation Analysis of the SHOX2 and RASSF1A Panel in Bronchoalveolar Lavage Fluid for Lung Cancer Diagnosis. J Cancer, 2017, 8(17): 3585-3591.
25. Hubers AJ, Prinsen CF, Sozzi G, et al. Molecular sputum analysis for the diagnosis of lung cancer. Br J Cancer, 2013, 109(3): 530-537.
26. Hubers AJ, Heideman DA, Duin S, et al. DNA hypermethylation analysis in sputum of asymptomatic subjects at risk for lung cancer participating in the NELSON trial: argument for maximum screening interval of 2 years. J Clin Pathol, 2017, 70(3): 250-254.
27. Hubers AJ, Heideman DAM, Burgers SA, et al. DNA hypermethylation analysis in sputum for the diagnosis of lung cancer: training validation set approach. British journal of cancer, 2015, 112(6): 1105-1113.
28. Hubers AJ, van der Drift MA, Prinsen CF, et al. Methylation analysis in spontaneous sputum for lung cancer diagnosis. Lung Cancer, 2014, 84(2): 127-133.
29. Liloglou T, Bediaga NG, Brown BR, et al. Epigenetic biomarkers in lung cancer. Cancer Lett, 2014, 342(2): 200-212.
30. Hubers AJ, Heideman DAM, Herder GJM, et al. Prolonged sampling of spontaneous sputum improves sensitivity of hypermethylation analysis for lung cancer. J Clin Pathol, 2012, 65(6): 541.